JP2019182753A - Endo180 production promoter - Google Patents
Endo180 production promoter Download PDFInfo
- Publication number
- JP2019182753A JP2019182753A JP2018071341A JP2018071341A JP2019182753A JP 2019182753 A JP2019182753 A JP 2019182753A JP 2018071341 A JP2018071341 A JP 2018071341A JP 2018071341 A JP2018071341 A JP 2018071341A JP 2019182753 A JP2019182753 A JP 2019182753A
- Authority
- JP
- Japan
- Prior art keywords
- endo180
- production promoter
- lactobacillus plantarum
- endo180 production
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010013050 Endo180 Proteins 0.000 title claims abstract description 55
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 47
- 239000000284 extract Substances 0.000 claims abstract description 45
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 30
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 30
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 30
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 28
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 28
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 19
- 244000144730 Amygdalus persica Species 0.000 claims description 18
- 229930014626 natural product Natural products 0.000 abstract description 7
- 230000009471 action Effects 0.000 abstract description 6
- 244000060696 Alpinia speciosa Species 0.000 abstract description 5
- 235000013411 Alpinia speciosa Nutrition 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 25
- 238000000605 extraction Methods 0.000 description 21
- 102000008186 Collagen Human genes 0.000 description 19
- 108010035532 Collagen Proteins 0.000 description 19
- 229920001436 collagen Polymers 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 239000002609 medium Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 239000002994 raw material Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 239000000306 component Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- -1 phospholipase A2 Proteins 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010031099 Mannose Receptor Proteins 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010051246 Photodermatosis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040954 Skin wrinkling Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000001163 endosome Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012533 medium component Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000008845 photoaging Effects 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 235000020244 animal milk Nutrition 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- 102000009268 Collagen Receptors Human genes 0.000 description 1
- 108010048623 Collagen Receptors Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 1
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 1
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
- 201000010859 Milk allergy Diseases 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000004050 Phospholipase A2 Receptors Human genes 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000010039 intracellular degradation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Abstract
Description
本発明は、天然物由来成分を有効成分とするEndo180産生促進剤に関するものである。 The present invention relates to an Endo180 production promoter containing a natural product-derived component as an active ingredient.
紫外線の長期曝露によって引き起こされる光老化では、真皮コラーゲン線維構造の量的、質的変化が確認されており、シワの形成に関与していると考えられている。コラーゲン線維構造は、コラーゲン線維の合成および分解の繰り返しによる代謝バランスによって恒常性が維持されている。このうち分解過程においては、マトリックスメタロプロテアーゼによるコラーゲンの断片化と、断片化されたコラーゲンの線維芽細胞への取り込みおよび分解とが起こっており、断片化コラーゲンの細胞内への取り込みには、膜タンパク質であるコラーゲンレセプター「Endo180」の関与が知られている(非特許文献1)。 In photoaging caused by long-term exposure to ultraviolet rays, quantitative and qualitative changes in the dermal collagen fiber structure have been confirmed, and it is considered to be involved in the formation of wrinkles. The collagen fiber structure is maintained in homeostasis by metabolic balance due to repeated synthesis and degradation of collagen fibers. In the degradation process, fragmentation of collagen by matrix metalloprotease and uptake and degradation of the fragmented collagen into fibroblasts occur. Involvement of collagen receptor “Endo180”, which is a protein, is known (Non-patent Document 1).
Endo180は、マンノース受容体C2(MRC2)、ウロキナーゼプラスミノーゲン活性化因子受容体関連タンパク質(uPARAP)およびCD280としても知られ、再利用されるエンドサイトーシス受容体であり、コラーゲンなどのリガンドと結合してこれを細胞内に取り込み、エンドソームにおける分解へと誘導する。 Endo180, also known as mannose receptor C2 (MRC2), urokinase plasminogen activator receptor associated protein (uPARAP) and CD280, is a re-used endocytosis receptor that binds to ligands such as collagen This is taken up into cells and induced to degrade in endosomes.
Endo180は、マクロファージマンノース受容体ファミリーであるマンノース受容体、ホスホリパーゼA2、DEC−205/MR6などと相同性を有する。Endo180は、細胞膜から、後期エンドソーム/リソソーム区画までではなく、リサイクリングエンドソームまでが標的とされるという点で、マンノース受容体のファミリーの中でも特殊であり、細胞遊走、および細胞内分解のためのコラーゲンの取り込みを促進することによって、細胞運動性や細胞外マトリックスの再構築において機能を果たす。また、uPARAPとして、ウロキナーゼ型プラスミン活性化因子(uPA)およびウロキナーゼ型プラスミン活性化因子受容体(uPAR)と三重複合体を形成し、プラスミノーゲンからのプラスミンの生成に関与する。Endo180は、細胞表面上のクラスリンで覆われたピットや、エンドソーム等に局在しており、線維芽細胞、内皮細胞、およびマクロファージにおいて主に発現する。組織としては、肺、血管、骨および皮膚において主に発現している(特許文献1参照)。 Endo180 has homology with the mannose receptor, phospholipase A2, DEC-205 / MR6, and the like, which are the macrophage mannose receptor family. Endo180 is unique among the family of mannose receptors in that it is targeted to the recycling endosome rather than the cell membrane to the late endosomal / lysosomal compartment, and is a collagen for cell migration and intracellular degradation. It promotes cell uptake and functions in cell motility and extracellular matrix remodeling. In addition, uPARAP forms a ternary complex with urokinase-type plasmin activator (uPA) and urokinase-type plasmin activator receptor (uPAR), and is involved in the production of plasmin from plasminogen. Endo180 is localized in pits covered with clathrin on the cell surface, endosomes, and the like, and is mainly expressed in fibroblasts, endothelial cells, and macrophages. As a tissue, it is mainly expressed in lungs, blood vessels, bones and skin (see Patent Document 1).
一方、皮膚の真皮もコラーゲンに富む組織であるが、真皮中のコラーゲン線維のリモデリングにおけるEndo180の関与に関する報告は少ない。これまでに、光老化皮膚では線維芽細胞においてEndo180発現が低下し、それに伴い真皮マトリックスにおいて断片化コラーゲンが蓄積されることが知られている(非特許文献2)。また、断片化コラーゲンによって線維芽細胞に酸化ストレスが誘導されることが知られている(非特許文献3)。さらに、紫外線によるEndo180発現低下メカニズムにケラチノサイトが産生するIL−1αが関与していることも知られている(非特許文献4)。これらのことから、Endo180は、紫外線の長期曝露によって引き起こされる光老化皮膚の形成(例えば、シワの形成)に関与しているものと考えられている。そのメカニズムとしては、線維芽細胞においてEndo180の発現が低下すると、断片化コラーゲンの取り込みが抑えられることで正常なコラーゲン線維構造の再生が阻害され、また細胞の周辺に断片化コラーゲンが蓄積することにより線維芽細胞の機能障害を誘導するものと考えられる。 On the other hand, although the dermis of the skin is also a tissue rich in collagen, there are few reports regarding the involvement of Endo180 in remodeling of collagen fibers in the dermis. So far, it has been known that Endo180 expression is decreased in fibroblasts in photoaged skin, and fragmented collagen is accumulated in the dermal matrix accordingly (Non-patent Document 2). Further, it is known that oxidative stress is induced in fibroblasts by fragmented collagen (Non-patent Document 3). Furthermore, it is also known that IL-1α produced by keratinocytes is involved in the mechanism of lowering Endo180 expression by ultraviolet light (Non-patent Document 4). From these facts, Endo180 is considered to be involved in the formation of photoaged skin (for example, the formation of wrinkles) caused by long-term exposure to ultraviolet rays. As the mechanism, when the expression of Endo180 in fibroblasts decreases, the uptake of fragmented collagen is suppressed, so that the regeneration of normal collagen fiber structure is inhibited, and the fragmented collagen accumulates around the cells. It is thought to induce dysfunction of fibroblasts.
そのため、例えば、線維芽細胞においてEndo180発現を促進することができれば、断片化したコラーゲンの代謝による再利用や正常なコラーゲン線維構造の再生を促し、光老化皮膚やこれによるシワ等の形成を抑えることができると考えられる。 Therefore, for example, if Endo180 expression can be promoted in fibroblasts, it promotes reuse of fragmented collagen by metabolism and regeneration of normal collagen fiber structure, and suppresses the formation of photoaged skin and wrinkles due to this. It is thought that you can.
本発明は、安全性の高い天然物由来成分の中から、優れたEndo180産生促進作用を有するものを見出し、それを有効成分とするEndo180産生促進剤を提供することを目的とする。 An object of the present invention is to find an endo180 production promoting agent having an excellent endo180 production promoting action from among highly safe natural product-derived components, and to provide an endo180 production promoting agent comprising the same.
上記課題を解決するために、本発明のEndo180産生促進剤は、ハス胚芽抽出物、月桃葉抽出物およびラクトバシルス・プランタラムからなる群より選択される1種または2種以上を有効成分とすることを特徴とする。 In order to solve the above-mentioned problems, the Endo180 production promoter of the present invention comprises, as an active ingredient, one or more selected from the group consisting of lotus germ extract, moon peach leaf extract, and Lactobacillus plantarum It is characterized by.
本発明によれば、天然物に由来するハス胚芽抽出物、月桃葉抽出物およびラクトバシルス・プランタラムからなる群より選択される1種または2種以上を有効成分として用いることにより、作用効果に優れ、かつ安全性の高いEndo180産生促進剤を提供することができる。 According to the present invention, by using one or more selected from the group consisting of a lotus germ extract derived from a natural product, a moon peach leaf extract, and a Lactobacillus plantarum as an active ingredient, the effect is excellent. And, Endo180 production promoter with high safety can be provided.
以下、本発明の実施の形態について説明する。
本実施形態のEndo180産生促進剤は、ハス胚芽抽出物、月桃葉抽出物およびラクトバシルス・プランタラムからなる群より選択される1種または2種以上を有効成分とするものである。
Embodiments of the present invention will be described below.
The Endo180 production promoter of this embodiment has one or more selected from the group consisting of a lotus germ extract, a moon peach leaf extract, and a Lactobacillus plantarum as an active ingredient.
〔ハス胚芽抽出物,月桃葉抽出物〕
本実施形態で用いるハス胚芽抽出物および月桃葉抽出物は、ハス(学名:Nelumbo nucifera Gaertn.)および月桃(学名:Alpinia zerumbetまたはAlpinia speciosa (Wendl.) K. Schum.)から得られる抽出物である。
[Lotus germ extract, moon peach leaf extract]
The lotus germ extract and moon peach leaf extract used in this embodiment are extracts obtained from lotus (scientific name: Nelumbo nucifera Gaertn.) And moon peach (scientific name: Alpinia zerumbet or Alpinia speciosa (Wendl.) K. Schum.). It is.
ここで、本実施形態における「抽出物」には、上記天然物を抽出原料として得られる抽出液、当該抽出液の希釈液若しくは濃縮液、当該抽出液を乾燥して得られる乾燥物、又はこれらの粗精製物若しくは精製物のいずれもが含まれる。 Here, the “extract” in the present embodiment includes an extract obtained using the above natural product as an extraction raw material, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, or these Both of these crudely purified products and purified products are included.
ハス(Nelumbo nucifera Gaertn.)は、熱帯アジア原産のスイレン科ハス属に属する多年性水生植物である。ハスはわが国では地下茎の部分が蓮根として食されており、安全性の高い植物である。ハスは、ヨーロッパ東南部、オーストラリア北部、アジア東部などに分布しており、また池や水田、堀等に栽培され、これらの地域から容易に入手することができる。抽出原料として使用するハスの構成部位は、胚芽である。ハス胚芽とは、ハスの種子の中にある緑色で棒状の胚芽のことである。 The lotus (Nelumbo nucifera Gaertn.) Is a perennial aquatic plant belonging to the genus Lotusaceae native to tropical Asia. In Japan, lotus root is eaten as a lotus root in Japan and is a highly safe plant. Lotus is distributed in southeastern Europe, northern Australia, eastern Asia, etc., and is cultivated in ponds, paddy fields, moats, etc., and can be easily obtained from these areas. The constituent part of the lotus used as an extraction raw material is germ. The lotus germ is a green, rod-shaped germ in a lotus seed.
月桃(Alpinia zerumbetまたはAlpinia speciosa (Wendl.) K. Schum.)は、ショウガ科ハナミョウガ属に属する多年生常緑草本であり、九州南部からインドにまで分布しており、これらの地域から容易に入手することができる。月桃は、沖縄ではサンニンと呼ばれ、琉球王朝以来の伝統菓子であるムーチーに利用されるほか、ハーブとしても利用されている。抽出原料として使用する部位は、葉部である。 Tsuki Peach (Alpinia zerumbet or Alpinia speciosa (Wendl.) K. Schum.) Is a perennial evergreen herb belonging to the genus Glyceraceae and is distributed from southern Kyushu to India and is easily obtained from these regions be able to. Tsuki-Peach is called Sannin in Okinawa and is used in Muchy, a traditional confectionery since the Ryukyu dynasty. The part used as an extraction raw material is a leaf part.
上記天然物からの抽出物は、抽出原料を乾燥した後、そのまま又は粗砕機を用いて粉砕し、抽出溶媒による抽出に供することにより得ることができる。乾燥は天日で行ってもよいし、通常使用される乾燥機を用いて行ってもよい。また、ヘキサン等の非極性溶媒によって脱脂等の前処理を施してから抽出原料として使用してもよい。脱脂等の前処理を行うことにより、上記抽出原料の極性溶媒による抽出処理を効率よく行うことができる。 The extract from the natural product can be obtained by drying the extraction raw material, pulverizing it as it is or using a crusher, and subjecting it to extraction with an extraction solvent. Drying may be performed in the sun or using a commonly used dryer. Moreover, after performing pretreatment, such as degreasing, with a nonpolar solvent such as hexane, it may be used as an extraction raw material. By performing a pretreatment such as degreasing, the extraction material can be efficiently extracted with a polar solvent.
抽出溶媒としては、極性溶媒を使用することが好ましく、例えば、水、親水性有機溶媒等が挙げられ、これらを単独で又は2種以上を組み合わせて、室温又は溶媒の沸点以下の温度で使用することが好ましい。 As the extraction solvent, it is preferable to use a polar solvent, and examples thereof include water and hydrophilic organic solvents. These are used alone or in combination of two or more at room temperature or a temperature below the boiling point of the solvent. It is preferable.
抽出溶媒として使用し得る水としては、純水、水道水、井戸水、鉱泉水、鉱水、温泉水、湧水、淡水等のほか、これらに各種処理を施したものが含まれる。水に施す処理としては、例えば、精製、加熱、殺菌、濾過、イオン交換、浸透圧調整、緩衝化等が含まれる。したがって、本実施形態において抽出溶媒として使用し得る水には、精製水、熱水、イオン交換水、生理食塩水、リン酸緩衝液、リン酸緩衝生理食塩水等も含まれる。 Examples of water that can be used as the extraction solvent include pure water, tap water, well water, mineral spring water, mineral water, hot spring water, spring water, fresh water, and the like, and those subjected to various treatments. Examples of the treatment applied to water include purification, heating, sterilization, filtration, ion exchange, osmotic pressure adjustment, buffering, and the like. Therefore, the water that can be used as the extraction solvent in this embodiment includes purified water, hot water, ion exchange water, physiological saline, phosphate buffer, phosphate buffered saline, and the like.
抽出溶媒として使用し得る親水性有機溶媒としては、メタノール、エタノール、プロピルアルコール、イソプロピルアルコール等の炭素数1〜5の低級脂肪族アルコール;アセトン、メチルエチルケトン等の低級脂肪族ケトン;1,3−ブチレングリコール、プロピレングリコール、グリセリン等の炭素数2〜5の多価アルコール等が挙げられる。 Examples of hydrophilic organic solvents that can be used as extraction solvents include lower aliphatic alcohols having 1 to 5 carbon atoms such as methanol, ethanol, propyl alcohol, and isopropyl alcohol; lower aliphatic ketones such as acetone and methyl ethyl ketone; 1,3-butylene. Examples thereof include polyhydric alcohols having 2 to 5 carbon atoms such as glycol, propylene glycol and glycerin.
2種以上の極性溶媒の混合液を抽出溶媒として使用する場合、その混合比は適宜調整することができる。例えば、水と低級脂肪族アルコールとの混合液を抽出溶媒として使用する場合には、水と低級脂肪族アルコールとの混合比が9:1〜1:9(容量比)であることが好ましく、7:3〜2:8(容量比)であることがさらに好ましい。また、水と低級脂肪族ケトンとの混合液を使用する場合には、水と低級脂肪族ケトンとの混合比が9:1〜2:8(容量比)であることが好ましく、水と多価アルコールとの混合液を使用する場合には、水と多価アルコールとの混合比が8:2〜1:9(容量比)であることが好ましい。 When using the liquid mixture of 2 or more types of polar solvents as an extraction solvent, the mixing ratio can be adjusted suitably. For example, when a mixed liquid of water and lower aliphatic alcohol is used as an extraction solvent, the mixing ratio of water and lower aliphatic alcohol is preferably 9: 1 to 1: 9 (volume ratio), More preferably, it is 7: 3 to 2: 8 (capacity ratio). In addition, when a mixed liquid of water and a lower aliphatic ketone is used, the mixing ratio of water and the lower aliphatic ketone is preferably 9: 1 to 2: 8 (volume ratio). When using the liquid mixture with a monohydric alcohol, it is preferable that the mixing ratio of water and a polyhydric alcohol is 8: 2 to 1: 9 (volume ratio).
抽出処理は、抽出原料に含まれる可溶性成分を抽出溶媒に溶出させ得る限り特に限定はされず、常法に従って行うことができる。例えば、抽出原料の5〜15倍量(質量比)の抽出溶媒に、抽出原料を浸漬し、常温又は還流加熱下で可溶性成分を抽出させた後、濾過して抽出残渣を除去することにより抽出液を得ることができる。得られた抽出液から溶媒を留去するとペースト状の濃縮物が得られ、この濃縮物をさらに乾燥すると乾燥物が得られる。 The extraction treatment is not particularly limited as long as the soluble component contained in the extraction raw material can be eluted in the extraction solvent, and can be performed according to a conventional method. For example, the extraction raw material is immersed in an extraction solvent 5 to 15 times (mass ratio) of the extraction raw material, the soluble components are extracted at room temperature or under reflux, and then filtered to remove the extraction residue. A liquid can be obtained. When the solvent is distilled off from the obtained extract, a paste-like concentrate is obtained, and when this concentrate is further dried, a dried product is obtained.
以上のようにして得られるハス胚芽抽出物および月桃葉抽出物は、優れたEndo180産生促進作用を有しているため、Endo180産生促進剤の有効成分として用いることができる。 Since the lotus germ extract and moon peach leaf extract obtained as described above have an excellent Endo180 production promoting action, they can be used as an active ingredient of an Endo180 production promoter.
〔ラクトバシルス・プランタラム〕
本実施形態においては、ラクトバシルス・プランタラム(Lactobacillus plantarum)も用いることができる。ラクトバシルス・プランタラムは、乳酸菌の一種であるが、主として野菜漬物、キムチ、味噌などの植物性の発酵食品から分離されることから植物性乳酸菌に包含され、ヨーグルト等の発酵乳や乳酸菌飲料の製造に用いられる動物性乳酸菌とは異なるものである。
[Lactobacillus plantarum]
In this embodiment, Lactobacillus plantarum can also be used. Lactobacillus plantarum is a kind of lactic acid bacteria, but it is included in plant lactic acid bacteria because it is mainly isolated from vegetable fermented foods such as vegetable pickles, kimchi, miso, etc., producing fermented milk such as yogurt and lactic acid bacteria beverages It is different from animal lactic acid bacteria used in
本実施形態においては、ラクトバシルス・プランタラムに分類される乳酸菌であれば何れを用いてもよいが、後述する作用効果が好ましく発揮されることから、ラクトバシルス・プランタラム 22A−1(FERM P−21409)、ラクトバシルス・プランタラム 22A−3(FERM P−21411)、およびラクトバシルス・プランタラム 22B−2(FERM P−21410)からなる群より選択される1または2以上であることが好ましく、ラクトバシルス・プランタラム 22A−3(FERM P−21411)であることが特に好ましい。 In this embodiment, any lactic acid bacteria classified into Lactobacillus plantarum may be used, but since the effects described below are preferably exhibited, Lactobacillus plantarum 22A-1 (FERM P-21409) ), Lactobacillus plantarum 22A-3 (FERM P-21411), and Lactobacillus plantarum 22B-2 (FERM P-21410). Talam 22A-3 (FERM P-21411) is particularly preferable.
なお、上記ラクトバシルス・プランタラム 22A−1(FERM P−21409)、ラクトバシルス・プランタラム 22A−3(FERM P−21411)、およびラクトバシルス・プランタラム 22B−2(FERM P−21410)の3株は、本発明者らにより漬物から単離・同定された株であり、独立行政法人産業技術総合研究所 特許生物寄託センターに寄託されている。 The three strains of Lactobacillus plantarum 22A-1 (FERM P-21409), Lactobacillus plantarum 22A-3 (FERM P-21411), and Lactobacillus plantarum 22B-2 (FERM P-21410) are: It is a strain isolated and identified from pickles by the present inventors and deposited with the Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology.
本実施形態においては、上記ラクトバシルス・プランタラムを培養により増殖させることで、大量に取得することができる。上記ラクトバシルス・プランタラムを培養する培地としては特に制限はされず、乳酸菌の培養に通常使用される培地やその改変培地を使用することができる。このような培地に配合される培地成分としては、例えば、グルコース等の炭素源;酵母エキス、肉エキス、カゼイン等およびこれらのタンパク加水分解物等の窒素源;塩化ナトリウム、リン酸ナトリウム、リン酸カリウム、クエン酸アンモニウム、硫酸マグネシウム等の無機塩類;チアミン、イノシトール等のビタミン類などの、乳酸菌の生育に好適な成分などが挙げられる。また、食品素材として利用可能な植物材料等を含む培地を用いてもよい。
なお、本実施形態においては、培地成分として動物の乳由来の成分を用いなくてもよい。培地成分に動物の乳由来の成分を用いた場合、乳アレルギーを惹起する可能性があることからアレルギー患者による使用が制限されることがあり、また、乳酸菌を培養することで好ましくない香気を生じさせることがあることから化粧料の配合成分として適当でない場合がある。
In this embodiment, a large amount can be obtained by growing the Lactobacillus plantarum by culturing. The medium for culturing the Lactobacillus plantarum is not particularly limited, and a medium usually used for culturing lactic acid bacteria or a modified medium thereof can be used. Examples of medium components to be mixed in such a medium include carbon sources such as glucose; nitrogen sources such as yeast extract, meat extract, casein, and protein hydrolysates thereof; sodium chloride, sodium phosphate, and phosphoric acid. Inorganic salts such as potassium, ammonium citrate, and magnesium sulfate; and components suitable for the growth of lactic acid bacteria, such as vitamins such as thiamine and inositol. Moreover, you may use the culture medium containing the plant material etc. which can be utilized as a foodstuff raw material.
In the present embodiment, it is not necessary to use a component derived from animal milk as a medium component. When ingredients derived from animal milk are used as medium components, they may cause milk allergy, which may limit the use by allergic patients. In addition, culturing lactic acid bacteria produces undesirable aromas. In some cases, it may not be suitable as a cosmetic ingredient.
上記ラクトバシルス・プランタラムの培養において、培地の形態、pH、培養温度、培養時間、培養方法等の培養条件は、特に限定されるものではなく、従来公知の条件を採用することができる。例えば、培地は液体培地でも固体培地でもよく、培養温度は、好ましくは25〜45℃、より好ましくは30〜37℃とすることができ、培養時間は、好ましくは4〜74時間、より好ましくは18〜48時間とすることができる。また、液体培地である場合、培養方法としては、静置、攪拌、振盪、通気等が挙げられるが、いずれを採用してもよい。 In the culture of Lactobacillus plantarum, the culture conditions such as the form of the medium, pH, culture temperature, culture time, culture method, etc. are not particularly limited, and conventionally known conditions can be employed. For example, the medium may be a liquid medium or a solid medium, and the culture temperature is preferably 25 to 45 ° C., more preferably 30 to 37 ° C., and the culture time is preferably 4 to 74 hours, more preferably It can be 18 to 48 hours. Further, in the case of a liquid medium, examples of the culture method include standing, stirring, shaking, aeration, etc., any of which may be adopted.
得られた培養物は、培地と菌体とを分離せずそのまま用いてもよく、培地と菌体とを分離して菌体を回収してもよい。菌体を回収する場合の方法も特に制限されず、例えば、液体培地であれば、遠心分離、濾過等によることができ、また固体培地であればセルスクレーパー等を用いて菌体を回収することができる。 The obtained culture may be used as it is without separating the medium and the cells, or the cells may be recovered by separating the medium and the cells. The method for recovering the bacterial cells is not particularly limited. For example, if it is a liquid medium, it can be centrifuged, filtered, etc. If it is a solid medium, the bacterial cells can be recovered using a cell scraper or the like. Can do.
得られたラクトバチルス・プランタラムの菌体は、生菌体をそのまま用いてもよいが、安全性の観点から死菌体を用いることが好ましい。死菌体とする方法は特に限定されず、菌体を含む培養物または回収した菌体に対し、加熱処理、加熱加圧処理、紫外線処理などの公知の方法にて行えばよい。また、得られた菌体は、さらに破砕等を行ってもよく、破砕物をさらに分画してもよい。 The obtained bacterial cells of Lactobacillus plantarum may use live cells as they are, but it is preferable to use dead cells from the viewpoint of safety. The method for making dead cells is not particularly limited, and the culture containing the cells or the collected cells may be performed by a known method such as heat treatment, heat and pressure treatment, or ultraviolet treatment. Moreover, the obtained microbial cells may be further crushed or the crushed material may be further fractionated.
以上のようにして得られるラクトバシルス・プランタラムは、優れたEndo180産生促進作用を有しているため、Endo180産生促進剤の有効成分として用いることができる。 Since the Lactobacillus plantarum obtained as described above has an excellent Endo180 production promoting action, it can be used as an active ingredient of an Endo180 production promoter.
〔Endo180産生促進剤〕
本実施形態のEndo180産生促進剤は、前述のようにして得られたハス胚芽抽出物、月桃葉抽出物およびラクトバシルス・プランタラムからなる群より選択される1種または2種以上を有効成分とするものである。本実施形態のEndo180産生促進剤は、医薬品、医薬部外品、飲食品、化粧品等の幅広い用途に使用することができる。
[Endo180 production promoter]
The Endo180 production promoter of the present embodiment has one or more selected from the group consisting of the lotus germ extract, moon peach leaf extract, and Lactobacillus plantarum obtained as described above as active ingredients. Is. The Endo180 production promoter of this embodiment can be used for a wide range of uses such as pharmaceuticals, quasi drugs, foods and drinks, and cosmetics.
本実施形態のEndo180産生促進剤は、ハス胚芽抽出物、月桃葉抽出物もしくはラクトバシルス・プランタラムまたはこれらの混合物のみからなるものでもよいし、ハス胚芽抽出物、月桃葉抽出物もしくはラクトバシルス・プランタラムまたはこれらの混合物を製剤化したものでもよい。 The Endo180 production promoter of this embodiment may consist of a lotus germ extract, moon peach leaf extract or Lactobacillus plantarum or a mixture thereof, or a lotus germ extract, moon peach leaf extract or Lactobacillus plantarum. Alternatively, a mixture of these may be formulated.
本実施形態のEndo180産生促進剤は、デキストリン、シクロデキストリン等の薬学的に許容し得るキャリアーその他任意の助剤を用いて、常法に従い、粉末状、顆粒状、錠剤状、液状等の任意の剤形に製剤化することができる。この際、助剤としては、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、安定剤、矯味・矯臭剤等を用いることができる。Endo180産生促進剤は、他の組成物(例えば、飲食品、皮膚化粧料等)に配合して使用することができるほか、軟膏剤、外用液剤、貼付剤等として使用することができる。 The Endo180 production promoter of this embodiment is an arbitrary pharmaceutically acceptable carrier such as dextrin, cyclodextrin, etc., and any other auxiliary agent according to a conventional method, such as powder, granule, tablet, liquid, etc. It can be formulated into a dosage form. In this case, as an auxiliary agent, for example, an excipient, a binder, a disintegrant, a lubricant, a stabilizer, a flavoring / flavoring agent, and the like can be used. The Endo180 production promoter can be used by blending with other compositions (for example, foods and drinks, skin cosmetics, etc.), and can also be used as an ointment, a liquid for external use, a patch and the like.
本実施形態のEndo180産生促進剤を製剤化した場合、ハス胚芽抽出物、月桃葉抽出物もしくはラクトバシルス・プランタラムまたはこれらの混合物の含有量は、特に限定されるものではなく、目的に応じて適宜設定することができる。 When the Endo180 production promoter of this embodiment is formulated, the content of the lotus germ extract, moon peach leaf extract or Lactobacillus plantarum or a mixture thereof is not particularly limited, and is appropriately determined according to the purpose. Can be set.
なお、本実施形態のEndo180産生促進剤は、必要に応じて、Endo180産生促進作用を有する他の天然抽出物等を、ハス胚芽抽出物、月桃葉抽出物もしくはラクトバシルス・プランタラムまたはこれらの混合物とともに配合して有効成分として用いることができる。 In addition, the Endo180 production promoter of this embodiment may contain other natural extracts having an Endo180 production promoting action, together with a lotus germ extract, moon peach leaf extract, Lactobacillus plantarum, or a mixture thereof, as necessary. It can mix | blend and can be used as an active ingredient.
本実施形態のEndo180産生促進剤の患者に対する投与方法としては、経皮投与、経口投与等が挙げられるが、疾患の種類に応じて、その予防・治療等に好適な方法を適宜選択すればよい。また、本実施形態のEndo180産生促進剤の投与量も、疾患の種類、重症度、患者の個人差、投与方法、投与期間等によって適宜増減すればよい。 Examples of the administration method of the Endo180 production promoter of this embodiment to a patient include transdermal administration, oral administration, and the like, but a suitable method for the prevention / treatment or the like may be appropriately selected according to the type of disease. . Further, the dose of the Endo180 production promoter of this embodiment may be appropriately increased or decreased depending on the disease type, severity, individual differences among patients, administration method, administration period, and the like.
本実施形態のEndo180産生促進剤は、有効成分であるハス胚芽抽出物、月桃葉抽出物およびラクトバシルス・プランタラムが有するEndo180産生促進作用を通じて、線維芽細胞においてEndo180の産生を促進し、これにより、エンドサイトーシスによる断片化コラーゲンの取り込みを促進して正常なコラーゲン線維構造の再生を促し、シワの形成等といった皮膚の光老化症状を予防、治療または改善することができる。また、本実施形態のEndo180産生促進剤は、正常なコラーゲン線維構造の再生を促すことにより、慢性関節リウマチ、変形性関節炎、化膿性関節炎、痛風性関節炎、外傷性関節炎、骨関節炎等の関節炎の予防、治療または改善などの用途に用いることができる。ただし、本実施形態のEndo180産生促進剤は、これらの用途以外にも上記作用を発揮することに意義のあるすべての用途に用いることができる。 The Endo180 production promoter of this embodiment promotes the production of Endo180 in fibroblasts through the Endo180 production promotion action of the Lotus germ extract, moon peach leaf extract and Lactobacillus plantarum, which are active ingredients, By promoting the uptake of fragmented collagen by endocytosis to promote the regeneration of normal collagen fiber structure, it is possible to prevent, treat or ameliorate skin photoaging symptoms such as wrinkle formation. Further, the Endo180 production promoter of the present embodiment promotes regeneration of normal collagen fiber structure, thereby preventing arthritis such as rheumatoid arthritis, osteoarthritis, purulent arthritis, gouty arthritis, traumatic arthritis, osteoarthritis and the like. It can be used for applications such as prevention, treatment or improvement. However, the Endo180 production promoter of this embodiment can be used for all the uses meaningful in exhibiting the said effect | action besides these uses.
また、本実施形態のEndo180産生促進剤は、優れたEndo180産生促進作用を有するため、例えば、飲食品や皮膚外用剤に配合するのに好適である。この場合に、ハス胚芽抽出物、月桃葉抽出物もしくはラクトバシルス・プランタラムまたはこれらの混合物をそのまま配合してもよいし、ハス胚芽抽出物、月桃葉抽出物もしくはラクトバシルス・プランタラムまたはこれらの混合物から製剤化したEndo180産生促進剤を配合してもよい。 Moreover, since the Endo180 production promoter of this embodiment has the outstanding Endo180 production promotion effect | action, it is suitable for mix | blending with food-drinks and a skin external preparation, for example. In this case, the lotus germ extract, moon peach leaf extract or Lactobacillus plantarum or a mixture thereof may be blended as it is, or the lotus germ extract, moon peach leaf extract or Lactobacillus plantarum or a mixture thereof. You may mix | blend the formulated Endo180 production promoter.
ここで、飲食品とは、人の健康に危害を加えるおそれが少なく、通常の社会生活において、経口又は消化管投与により摂取されるものをいい、行政区分上の食品、医薬品、医薬部外品等の区分に制限されるものではない。したがって、本実施形態における「飲食品」は、経口的に摂取される一般食品、健康食品(機能性飲食品)、保健機能食品(特定保健用食品,栄養機能食品、機能性表示食品)、医薬部外品、医薬品等を幅広く含むものである。 Here, food and drink are those that are less likely to harm human health and are taken by oral or gastrointestinal administration in normal social life. It is not limited to such categories. Therefore, the “food and drink” in the present embodiment includes general foods taken orally, health foods (functional foods and drinks), health functional foods (specific health foods, nutritional functional foods, functional foods), pharmaceuticals It includes a wide range of quasi-drugs and pharmaceuticals.
皮膚外用剤としては、その区分に制限はなく、経皮的に使用される皮膚化粧料、医薬部外品、医薬品等を幅広く含むものであり、具体的には、例えば、軟膏、クリーム、乳液、化粧水、美容液、ローション、ジェル、美容オイル、パック、ファンデーション、リップクリーム、入浴剤、ヘアートニック、ヘアーローション、シャンプー、リンス、石鹸、ボディシャンプー等が挙げられる。 The topical skin preparation is not limited in its category, and includes a wide range of skin cosmetics, quasi-drugs, pharmaceuticals, and the like used transdermally. Specifically, for example, ointments, creams, and emulsions. , Lotions, cosmetic liquids, lotions, gels, cosmetic oils, packs, foundations, lip balms, bath salts, hair nicks, hair lotions, shampoos, rinses, soaps, body shampoos and the like.
また、本実施形態のEndo180産生促進剤は、優れたEndo180産生促進作用を有するので、これらの作用機構に関する研究のための試薬としても好適に利用することができる。 Moreover, since the Endo180 production promoter of this embodiment has the outstanding Endo180 production promotion effect | action, it can be utilized suitably also as a reagent for the research regarding these action mechanisms.
なお、本実施形態のEndo180産生促進剤は、ヒトに対して好適に適用されるものであるが、それぞれの作用効果が奏される限り、ヒト以外の動物(例えば,マウス,ラット,ハムスター,イヌ,ネコ,ウシ,ブタ,サル等)に対して適用することもできる。 The Endo180 production promoter of this embodiment is suitably applied to humans, but as long as each effect is exhibited, animals other than humans (for example, mice, rats, hamsters, dogs). , Cats, cattle, pigs, monkeys, etc.).
以下、試験例を示し、本発明を具体的に説明するが、本発明は下記の各例に何ら制限されるものではない。なお、下記試験例においては、被験試料として、ハス胚芽抽出物(丸善製薬社製,試料1)、月桃葉抽出物(丸善製薬社製,試料2)、およびラクトバシルス・プランタラム死菌体(丸善製薬社製,試料3)を使用した(いずれも凍結乾燥品)。 Hereinafter, although a test example is shown and this invention is demonstrated concretely, this invention is not restrict | limited to each following example at all. In the following test examples, lotus germ extract (manufactured by Maruzen Pharmaceutical, sample 1), moon peach leaf extract (manufactured by Maruzen Pharmaceutical, sample 2), and dead cells of Lactobacillus plantarum (maruzen) Samples 3) manufactured by Pharmaceutical Co., Ltd. were used (both lyophilized products).
〔試験例1〕Endo180産生促進作用試験
上記天然物由来成分(試料1〜3)について、以下のようにしてEndo180産生促進作用を試験した。
[Test Example 1] Endo180 production promoting action test The above-mentioned natural product-derived components (Samples 1 to 3) were tested for Endo180 production promoting action as follows.
ヒト正常皮膚線維芽細胞(NB1RGB)を、10%FBS含有ダルベッコMEMを用いて培養した後、トリプシン処理により細胞を回収した。回収した細胞を1.0×105 cells/mLの細胞密度になるよう0.25%FBS含有ダルベッコMEMで希釈した後、96ウェルマイクロプレートに1ウェル当たり100μLずつ播種し、二晩培養した。 Human normal skin fibroblasts (NB1RGB) were cultured using Dulbecco's MEM containing 10% FBS, and then cells were collected by trypsin treatment. The collected cells were diluted with Dulbecco's MEM containing 0.25% FBS to a cell density of 1.0 × 10 5 cells / mL, then seeded at 100 μL per well in a 96-well microplate, and cultured overnight.
培養終了後、培地を除去し、0.25%FBS含有ダルベッコMEMに溶解した被験試料(試料1〜3,試料濃度は下記表1を参照)を各ウェルに100μLずつ添加し、24時間培養した。なお、コントロールとして、試料無添加の0.25%FBS含有ダルベッコMEMを用いて同様に培養した。培養終了後、各ウェルの細胞表面に存在するEndo180量をELISA法により測定した。測定結果から、下記式によりEndo180産生促進率(%)を算出した。 After completion of the culture, the medium was removed, and 100 μL of each test sample dissolved in Dulbecco's MEM containing 0.25% FBS (samples 1 to 3; see Table 1 for sample concentration) was added to each well and cultured for 24 hours. . As a control, culturing was similarly performed using Dulbecco's MEM containing 0.25% FBS to which no sample was added. After completion of the culture, the amount of Endo180 present on the cell surface of each well was measured by ELISA. From the measurement results, Endo180 production promotion rate (%) was calculated by the following formula.
Endo180産生促進率(%)=A/B×100
式中の各項はそれぞれ以下を表す。
A:被験試料添加でのEndo180産生量
B:試料無添加でのEndo180産生量
結果を表1に示す。
Endo180 production promotion rate (%) = A / B × 100
Each term in the formula represents the following.
A: Endo180 production amount with addition of test sample B: Endo180 production amount without addition of sample Table 1 shows the results.
表1に示すように、ハス胚芽抽出物(試料1)、月桃葉抽出物(試料2)、およびラクトバシルス・プランタラム死菌体(試料3)は、いずれも優れたEndo180産生促進作用を有することが確認された。 As shown in Table 1, the lotus germ extract (sample 1), moon peach leaf extract (sample 2), and Lactobacillus plantarum dead cells (sample 3) all have an excellent Endo180 production promoting action. Was confirmed.
本発明のEndo180産生促進剤は、シワの形成等といった皮膚の光老化症状の予防、治療または改善;各種関節炎の予防、治療または改善;などに大きく貢献できる。 The Endo180 production promoter of the present invention can greatly contribute to the prevention, treatment or improvement of skin photoaging symptoms such as wrinkle formation; prevention, treatment or improvement of various arthritis.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018071341A JP7455344B2 (en) | 2018-04-03 | 2018-04-03 | Endo180 production promoter |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018071341A JP7455344B2 (en) | 2018-04-03 | 2018-04-03 | Endo180 production promoter |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019182753A true JP2019182753A (en) | 2019-10-24 |
JP7455344B2 JP7455344B2 (en) | 2024-03-26 |
Family
ID=68339570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018071341A Active JP7455344B2 (en) | 2018-04-03 | 2018-04-03 | Endo180 production promoter |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7455344B2 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002029980A (en) * | 2000-07-12 | 2002-01-29 | Maruzen Pharmaceut Co Ltd | Estrogenic agent and collagen production rpomoter, fibroblast proliferative agent, food for cosmetological use and skin cosmetic |
JP2011020965A (en) * | 2009-07-17 | 2011-02-03 | Maruzen Pharmaceut Co Ltd | Cosmetic kit, and method of makeup |
WO2013189694A2 (en) * | 2012-06-20 | 2013-12-27 | Beiersdorf Ag | Cosmetic and dermatological preparation containing one or more substances which modulate the gene / protein for the endo180 receptor |
WO2013189703A2 (en) * | 2012-06-20 | 2013-12-27 | Beiersdorf Ag | Cosmetic and dermatological preparation containing one or more substances which modulate the gene / protein for the endo180 receptor |
JP2017048244A (en) * | 2016-12-01 | 2017-03-09 | 株式会社東洋新薬 | Composition for collagen production promotion, composition for collagen absorption promotion, and composition for anti-obesity |
JP2017128538A (en) * | 2016-01-21 | 2017-07-27 | 丸善製薬株式会社 | Endo180 production promoter |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019109398A (en) | 2017-12-19 | 2019-07-04 | キヤノン株式会社 | Display device and display method |
-
2018
- 2018-04-03 JP JP2018071341A patent/JP7455344B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002029980A (en) * | 2000-07-12 | 2002-01-29 | Maruzen Pharmaceut Co Ltd | Estrogenic agent and collagen production rpomoter, fibroblast proliferative agent, food for cosmetological use and skin cosmetic |
JP2011020965A (en) * | 2009-07-17 | 2011-02-03 | Maruzen Pharmaceut Co Ltd | Cosmetic kit, and method of makeup |
WO2013189694A2 (en) * | 2012-06-20 | 2013-12-27 | Beiersdorf Ag | Cosmetic and dermatological preparation containing one or more substances which modulate the gene / protein for the endo180 receptor |
WO2013189703A2 (en) * | 2012-06-20 | 2013-12-27 | Beiersdorf Ag | Cosmetic and dermatological preparation containing one or more substances which modulate the gene / protein for the endo180 receptor |
JP2017128538A (en) * | 2016-01-21 | 2017-07-27 | 丸善製薬株式会社 | Endo180 production promoter |
JP2017048244A (en) * | 2016-12-01 | 2017-03-09 | 株式会社東洋新薬 | Composition for collagen production promotion, composition for collagen absorption promotion, and composition for anti-obesity |
Non-Patent Citations (1)
Title |
---|
TANG STEFANIE ET AL., JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 70, JPN6021048451, 2013, pages 42 - 48, ISSN: 0004785729 * |
Also Published As
Publication number | Publication date |
---|---|
JP7455344B2 (en) | 2024-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5235439B2 (en) | HMG-CoA reductase production promoter | |
JP6374579B2 (en) | Skin moisturizing function improving agent containing cyclic dipeptide as active ingredient | |
JP6969067B2 (en) | Anti-inflammatory, anti-aging and whitening agents | |
TWI776836B (en) | Composition for activating protein L-isoaspartate methyltransferase | |
JP7458660B2 (en) | Profilaggrin mRNA expression promoter, serine palmitoyltransferase mRNA expression promoter, and hyaluronic acid synthase 3 mRNA expression promoter | |
JP6055667B2 (en) | Collagen production promoter | |
JP6993076B2 (en) | Screening method for components that improve subcutaneous tissue structure | |
JP7455344B2 (en) | Endo180 production promoter | |
JP6846106B2 (en) | DKK1 expression promoter and whitening agent | |
JP2021143131A (en) | Anti-aging agent, skin cosmetic and oral composition | |
JP2021187787A (en) | Exosome secretagogue, exosome uptake promoter, exosome secretion-promoting beauty composition, and exosome secretion promoting method | |
JP2011032177A (en) | Inhibitor of kit cleavage | |
JP2014040487A (en) | Fat accumulation inhibitor | |
JP2018108973A (en) | Type xvii collagen production promoter | |
JP2014114251A (en) | Ceramide production promoter | |
JP2019048786A (en) | Novel collagen reuse promoting effect agent | |
JP6629271B2 (en) | Endo180 production promoter | |
JP7402478B2 (en) | Nerve growth factor expression inhibitor and semaphorin 3A expression promoter | |
JP7070902B2 (en) | Anti-aging agent and hyaluronic acid production promoter | |
WO2021125346A1 (en) | Method for activating skin stem cells through mpc1 suppression, and skin stem cell activation agent | |
JP2019516777A (en) | Whitening agent | |
JP2023102984A (en) | Endo180 production promoter | |
JP2017206477A (en) | Myogenesis promoting composition | |
JP6704106B2 (en) | Phenolic derivatives exhibiting cytoplasmic fluidity increasing action | |
JP6629036B2 (en) | Skin cosmetics and foods and drinks |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210303 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20211126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211207 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220531 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220831 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240306 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7455344 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |